The following presentations will include discussion of commercial products/services:

EP01.10, EP01.35, EP03.21, EP03.21, EP05.52 EP05.75, EP05.75, EP05.85, EP06.08, EP06.87, EP07.01, EP07.16, EP07.58, EP07.82, EP07.91, EP08.52, EP08.76, EP09.22, EP10.39, EP10.54, EP13.24, EP13.31, EP13.40, EP14.16, EP14.32, EP14.41, EP14.50, EP14.52, EP15.14, EP15.23, EP15.31, EP15.48, EP15.72, EP16.104, EP16.150, EP16.199, EP16.39 , EP16.39, EP16.57, EP16.71, EP17.22, EP18.13, OC06.02, OC08.04, OC08.06, OC10.04, OC14.04, OP01.01, OP02.04, OP02.05, OP02.06, OP04.03, OP05.02, OP07.01, OP09.01, OP11.03, OP14.05

The following presentations will include discussion of investigative or off label uses of products:

EP01.15, EP05.113, EP06.82, EP07.01, EP08.53, EP09.08, EP09.16, EP09.26, EP09.55, EP14.05, EP14.58, EP15.31, EP15.48, OC16.02, OC17.04

The following presentations will include discussion of clinical studies:

EP01.14, EP01.19, EP02.02, EP03.01, EP03.14, EP03.18, EP03.21, EP03.28, EP03.34, EP03.49, EP04.21, EP04.33, EP04.38, EP04.39, EP05.131, EP05.133, EP05.136, EP05.16, EP05.19, EP05.39, EP05.40, EP05.44, EP05.46, EP05.55, EP05.56, EP05.58, EP05.77, EP05.80, EP05.84, EP05.89, EP05.98, EP05.99, EP06.12, EP06.48, EP06.63, EP06.84, EP06.98, EP07.01, EP07.06, EP07.07, EP07.09, EP07.14, EP07.30, EP07.44, EP07.49, EP07.59, EP07.63, EP07.73, EP08.07, EP08.10, EP08.114, EP08.31, EP08.32, EP08.34, EP08.36, EP08.48, EP08.53, EP08.78, EP08.97, EP09.11, EP09.23, EP09.33, EP09.36, EP09.44, EP10.27, EP10.37, EP10.47, EP11.08, EP11.10, EP11.12, EP12.01, EP12.24, EP12.31, EP12.37, EP12.41, EP12.48, EP12.69, EP13.20, EP13.24, EP13.32, EP13.51, EP13.52, EP14.02, EP14.08, EP14.09, EP14.10, EP14.21, EP14.27, EP14.34, EP14.50, EP14.53, EP14.61, EP15.15, EP15.16, EP15.31, EP15.48, EP15.64, EP15.70, EP15.77, EP15.78, EP15.85, EP15.96, EP16.02, EP16.07, EP16.101, EP16.102, EP16.104, EP16.106, EP16.117, EP16.118, EP16.129, EP16.146, EP16.153, EP16.154, EP16.179, EP16.199, EP16.216, EP16.40, EP16.46, EP16.54, EP16.56, EP16.57, EP16.65, EP16.69, EP16.73, EP16.75, EP16.80, EP16.84, EP17.10, EP17.19, EP17.23, EP18.05, EP18.13, EP18.16, EP18.19, OC01.02, OC01.03, OC02.02, OC03.01, OC03.02, OC03.03, OC04.02, OC04.03, OC04.04, OC05.06, OC05.08, OC06.07, OC06.08, OC07.02, OC08.04, OC08.06, OC10.03, OC10.06, OC11.05, OC11.07, OC12.03, OC12.04 , OC12.05, OC13.02, OC13.05, OC13.07,OC14.04, OC14.07, OC16.02, OC16.03, OC16.05, OC16.06, OC17.04, OC17.06, OC17.08, OC18.02, OP01.01, OP01.06, OP02.04, OP02.05, OP04.04, OP04.05, OP05.01, OP05.05, OP06.01, OP08.04, OP09.03, OP10.03, OP11.06, OP11.07, OP15.02

The following presentations will include discussion of financial studies:

EP05.55, EP05.58, EP05.85, EP06.08, EP06.68, EP07.01, EP07.16, EP07.23, EP07.44, EP07.82, EP09.22, EP10.39, EP10.46, EP10.54, EP14.52, EP14.58, EP15.48, EP16.05, EP18.13, OC06.02, OC08.04, OC08.06, OP14.02

The following speaker declarations have been received:

  • Alex Novak: Loaned POCUS machines from GE and Philips. Unpublished, single centre.
  • Jena Miller: Published data will be described that involves the topic I will cover about placental cord insertions.
  • Karina Haratz: Research contracts with GE
  • Ivan Rosado-Mendez: I may discuss technology available on GE and Siemens ultrasound scanners. Research support provided by GE and Siemens. We'll discuss ongoing clinical research studies.
  • Aris Papageorghiou: I will disclose limitations
  • Liona Poon: Ultrasound machine, e.g. GE HealthCare, Samsung Healthcare, Mindray. In-kind contributions from GE HealthCare and Samsung Healthcare, Research funding from Mindray. Presentation of results based on research (partially supported by the aforementioned companies)
  • Robert de Leeuw: We will discuss several clinical trials regarding niches, adenomyosis and fibroids
  • Simon Meagher: Technical features of precision imaging. Receive honoraria fromy GE for educational events worldwide. Published papers from Pub Med.
  • Daniel Rolnik: Aspirin use in pregnancy is considered off label. Will discuss results of clinical trials and cohort studies and will discuss limitations.
  • Alfred Abuhamad: Diagnoly, Pulsenmore, Trice Imaging, Sonosim (Advisory Board)
  • Shabnam Bobdiwala: Published studies
  • Eduard Gratacos: I have a talk on artificial placenta, which is in experimental approach for extremely term babies. However, this is still an experimental prototype tested in animals and therefore I will discuss potential clinical applications from a theoretical point of view, not involving data from or recommendations about its use in humans. Pending of definitive acceptance by and permission from the journal, I will present the design (if not published yet) or the full results (if already published) of a randomised trial conducted by our team on the use of amniocentesis to aid in the management of preterm birth. If this is the case, I will acknowledge the limitations of the study as they are stated in the discussion of the paper
  • Jan Brosens: The presentation will include a description of how to measure the endometrial decidual reaction based on published biomarkers (https://www.science.org/doi/full/10.1126/sciadv.adv1988). These biomarkers have been patented by the University of Warwick. The University of Warwick also established a spinout company, Xambika (https://xambika.com/), to commercialise the biomarkers in a new endometrial test. The presentation will cover the biology of the biomarkers without direct reference to the commercial test. Although the presentation will be restricted to outlining the biology of published biomarkers and their clinical applications, my role as scientific founder and shareholder of Xambika will be disclosed. The presentation will include a discussion of published cohort studies (https://www.science.org/doi/full/10.1126/sciadv.adv1988)
  • Maya Almemar: Any published research study will be evaluated and the strengths and limitations highlighted to the audience
  • Chris Kyriacou: Latest publications to provided an evidence based talk to the delegates, but as always will discuss data limitations and critically appraise the work
  • Davor Jurkovic: Limitations will be discussed
  • Francesca Moro: Yes, the presentation includes discussion of both published research and possible ongoing clinical studies.
  • Rabih Chaoui: Honoraria from GE Healthcare
  • Ida Vogel: We have submitted this national implementation study to PND
  • Manel Mendoza: PlGF and sFlt-1 from Roche diagnostics. I received lecture and consulting fees from Roche diagnostics. The data presented are based on published and ongoing research and should be interpreted in the context of their respective study limitations.
  • Sharon Perlman: The presentation will include clinical studies, primarily small retrospective cohorts and case series, given the rarity of the conditions discussed. Limitations, including limited sample sizes, retrospective design, and the absence of prospective or controlled data for several of the entities presented, will be acknowledged during the talk.
  • Ahmet Baschat: Studies pertinent to Doppler surveillance in monochorionic twins.
  • Ohad Rotenberg: I will present a study which was recently published.
  • Dirk Timmerman: Gynaia.com may be mentioned. Co-founder and shareholder of Gynaia.com. I will discuss clinical studies and their limitations.
  • Laurent Salomon: Scientific advisor for Brightheart and Pulsenmore.
  • Stefan Kohl: Somatex Shunt
  • Christoph Lees: Unlikely but note I receive honoraria from GE and Samsung for speaking and directing webinars. I confirm that I will discuss limitations of interpretation of data
  • Aly Youssef: I use specific softwares that are useful in simplifying the examination of the pelvic floor, thus their citation is relevant to my presentation. I received consultancy fees from GE HealthCare for educational lectures and presentations.
  • Andrea Dall’Asta: Sponsored scan demonstration on 4th September at 12:00 pm - "Scan demonstration: AI for evaluation of key CNS structures"
  • Basky Thilaganathan: I occasionally undertake industry-sponsored talks or presentations on behalf of Samsung Medical and Toshiba Ultrasound. I will present limitations of data from clinical studies
  • Ritsuko Pooh: R.K.P. is Chief Executive Officer and a shareholder of Ritz Medical Co., Ltd., and receives executive compensation from the company. She also serves as a medical adviser to Japan Genetic Medicine Co., Ltd., for which she receives advisory fees, and receives speaking fees from GE HealthCare.
  • Jezid Miranda: I will detail this during my presentation
  • Tina Tellum: I will provide limitations of data
  • Lil Valentin: I ill refer to published studies with clinical content
  • Nina Cooper:  ADNEX model. I work for Gynaia who provide the medical device licence for ADNEX. I will discuss IOTA studies.
  • Tom Bourne:  The IOTA ADNEX application is now available through Gynaia. Inc - which I am a co-founder of. I cannot be specific at this stage as I have not made the presentation. All studies have limitations and these will be stated in the lecture.

Share